Search
Search
Invitrogen
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
图: 1 / 1
Imatinib is a 2-phenylaminopyrimidine derivative designed to inhibit the ATP binding site of protein kinases, specifically targeting the BCR-ABL tyrosine kinase, which is a result of the Philadelphia chromosome translocation. This competitive inhibition prevents the phosphorylation of substrates involved in BCR-ABL signaling, making it effective in treating chronic myelogenous leukemia and gastrointestinal stromal tumors. The structure-based analysis of imatinib derivatives has provided insights into its interaction with wild-type BCR-ABL and its mutants, suggesting potential for designing analogs with enhanced activity. Imatinib mesylate stabilizes the pre-folded parallel conformation of VEGF GQ through pi-pi stacking interactions, without altering the DNA structure.
仅用于科研。不用于诊断过程。未经明确授权不得转售。